Funded Startups in Needham
Across the 17 most recent Needham-linked funding entries, one disclosed round stands apart: Candel Therapeutics raised $100M on 2026-02-19, while the next-…
Across the 17 most recent Needham-linked funding entries, one disclosed round stands apart: Candel Therapeutics raised $100M on 2026-02-19, while the next-highest disclosed amounts are $30M (Silk, 2025-01-21) and $26M (knownwell, 2025-10-20). That concentration is reinforced by timing: 2025 accounts for most of the disclosed activity in this slice, with multiple rounds from 2025-01 through 2025-11 (e.g., Silk $30M on 2025-01-21; knownwell $26M on 2025-10-20; Soefia Education $210K on 2025-11-09). Sector-wise, biotechnology appears most often, showing up in 5 of the 17 entries (Remedium Bio on 2026-05-18; Candel Therapeutics on 2026-02-19; Convergent Dental on 2023-04-24; BioXyTran on 2023-03-13; Verastem Oncology on 2022-03-28), while stage labels are frequently missing or unclassified: 8 entries are “Series Unknown” and 1 is “undisclosed.” The dataset spans 2020-09-16 (MentorWorks Education Capital, $1M) through 2026-05-18 (Remedium Bio, $2M), with the most recent row dated 2026-05-18.
Most recent rounds
17 shownRelated listings
Frequently asked
What is the largest disclosed round in the Needham entries, and how does it compare to the rest of the disclosed amounts?
Candel Therapeutics’ $100M round on 2026-02-19 is the only disclosed figure above $50M; the next-largest disclosed amounts are $30M (Silk, 2025-01-21) and $26M (knownwell, 2025-10-20). That makes Candel’s disclosed amount a clear outlier relative to the rest of the disclosed rounds shown here.
How clustered are the rounds by time within this listing window?
Most rounds cluster in 2025 and into early 2025: examples include Silk $30M on 2025-01-21, XRHealth $6M on 2024-01-09, Newton Research $8M on 2025-05-15, and knownwell $26M on 2025-10-20. The slice also includes a distinct late-2026 uptick with Remedium Bio ($2M on 2026-05-18) following Candel Therapeutics ($100M on 2026-02-19).
Which sectors are over-represented in this Needham dataset?
Biotechnology is the most frequent sector, appearing in 5 of 17 entries (Remedium Bio on 2026-05-18; Candel Therapeutics on 2026-02-19; Convergent Dental on 2023-04-24; BioXyTran on 2023-03-13; Verastem Oncology on 2022-03-28). Other sectors in this slice appear fewer times (e.g., Education shows up in Soefia Education 2025-11-09 and MentorWorks Education Capital 2020-09-16).
Do stage labels cluster toward “unclassified,” and what does that mean for deal screening?
Stage is missing or unclassified for a large share: 8 entries are “Series Unknown,” and 1 entry lists the amount as “undisclosed” (Waterstone Properties Group, 2026-04-01). Only a subset has explicit stages such as Seed (Soefia Education $210K on 2025-11-09; Priority 5 $80K on 2022-09-14), Series B (knownwell $26M on 2025-10-20; Nobl9 $21M on 2021-02-10), or Series A (ClinOne $2M on 2023-11-01).
Are there low-end disclosed amounts that could be used as a baseline for diligence triage?
The smallest disclosed amount in the rows is $80K for Priority 5 on 2022-09-14, and there are other comparatively small disclosed rounds such as BioXyTran’s $130K on 2023-03-13 and Soefia Education’s $210K on 2025-11-09. These low-end figures contrast sharply with the $100M disclosed outlier from Candel Therapeutics on 2026-02-19.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.